CSE: WBIO

Last: 0.04

Change: 0.00

Vol: 0

View Polish site

About Us
Portfolio
- Overview
- Brain Cancer
  - WPD101
  - Berubicin
  - WP1066
- Pancreatic Cancer
  - WP1066
- Melanoma
  - WPD102
- Other Cancers
  - WPD103
  - WP1220
  - Annamycin
Investors
News & Media
- Latest News
- Events
Procurement/RFP
For Patient
Contact Us

About Us
Portfolio
- Overview
- Brain Cancer
  - WPD101
  - Berubicin
  - WP1066
- Pancreatic Cancer
  - WP1066
- Melanoma
  - WPD102
- Other Cancers
  - WPD103
  - WP1220
  - Annamycin
Investors
News & Media
- Latest News
- Events
Procurement/RFP
For Patient
Contact Us

CSE: WBIO

Last: 0.04

Change: 0.00

Vol: 0

Share Structure

Investors

Presentation
Stock Information
Share Structure
Financial Reports

Corporate Presentation
Download Fact Sheet
Download

Issued and Outstanding	111,520,388
Warrants	3,949,997
Fully diluted	115,470,385
Management & insiders holdings	36%

Subscribe to our Newsletter

About Us
Portfolio
Investors
News & Media
- Latest News
- Events
Procurement/RFP
For Patient
Contact Us

Corporate Head Office

WPD Pharmaceuticals Sp. z o.o.
Żwirki i Wigury 101, 02-089 Warszawa, Poland
National Court Register, Distrtict Court for the capital city of Warszawa in Warszawa, Poland
XII Commercial Division of the National Court Register
KRS: 0000693186, TAX Identification No.: 5252721500
Initial capital of PLN 2 969 200
Telephone No.: +48 515 262 381

Canada Corporate Office

Vancouver Office
Suite 1080, 789 West Pender Street
Vancouver, BC
V6C 1H2

Careers Privacy Policy Legal Note Cookies Policy © 2023 WPD Pharmaceuticals. All Rights Reserved

Designed and Powered by BLENDER